Humacyte Q3 Results: Symvess Revenue More Than Doubles as Commercial Adoption Expands
Durham, North Carolina-based biotechnology company Humacyte reported results for the third quarter ended September 30, 2026, on November 10, with revenue from its Symvess product more than doubling from a year earlier and commercial adoption continuing to expand.
The company said the supplemental biologics license application (sBLA) for its acellular tissue-engineered vessel (ATEV) for dialysis access is on track and is expected to be submitted to the U.S. Food and Drug Administration (FDA) within November 2026.
Humacyte also started the first-in-human Phase 2a clinical study of CTEV for coronary artery bypass grafting in November 2026, with the first clinical trial site activated. The company presented three reports on CTEV at the American Heart Association’s Scientific Sessions on November 7-8. Humacyte held a conference call at 8 a.m. Eastern on November 10 to discuss third-quarter results and business progress with investors. Humacyte is a commercial-stage biotechnology platform company developing universally implantable bioengineered human tissues.
Source: GlobeNewswire
Published by GSM · USA (original Chinese edition)
Photo: 实验室资料图。（Pexels）
